MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

International Journal of Oncology 2019 April 1 [Link] Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy arising from the pleura that is difficult to diagnose, contributing […]

Comments Off on Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, Yang D Abstract OBJECTIVE: The aim of our study was to investigate the expression of EGFR and PTEN in tissues and measure the serum platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to evaluate the prognostic factors of patients with epithelioid malignant peritoneal mesothelioma […]

Comments Off on Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

Molecular Biology Reports 2019 March 6 [Link] Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven […]

Comments Off on Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.

Radiology and Oncology 2019 March 3 [Link] Senk B, Goricar K, Kovac V, Dolzan V, Franko Abstract Background Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1 (AQP1) genetic polymorphisms influence the risk of MM and the response to cisplatin based […]

Comments Off on Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.

Frontiers in Oncology 2019 February 15 [Link] Zhou JG, Zhong H, Zhang J, Jin SH, Roudi R, Ma H Abstract Introduction: Dysregulated genes play a critical role in the development and progression of cancer, suggesting their potential as novel independent biomarkers for cancer diagnosis and prognosis. Prognostic model-based gene expression profiles are not widely utilized in […]

Comments Off on Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Human Pathology 2019 February 19 [Link] Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G Abstract Malignant mesothelioma (MM) is an aggressive neoplasm with poor prognosis. The Dako PD-L1 22C3 and 28-8 pharmDx assays are approved by the US Food and Drug Administration (FDA) as companion and complementary diagnostics for the anti-PD-1 […]

Comments Off on Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Current Treatment Options in Oncology 2019 February 14 [Link] Forde PM, Scherpereel A, Tsao AS Abstract Recent advances in immunology have extended into the mesothelioma field. To date, only Japan has given regulatory approval to salvage nivolumab in chemo-refractory mesothelioma patients. The USA has included in the NCCN guidelines that pembrolizumab (in programmed death ligand […]

Comments Off on Use of Immune Checkpoint Inhibitors in Mesothelioma.

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.

BMC Research Notes 2019 February 11 [Link] Weber DG1, Brik A2, Casjens S2, Burek K2, Lehnert M2, Pesch B2, Taeger D2, Brüning T2, Johnen G2; MoMar study group. Abstract Malignant mesothelioma is an aggressive cancer of the serous membranes. For the detection of the tumor at early stages non- or minimally-invasive biomarkers are needed. The […]

Comments Off on Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.

Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.

Anticancer Research 2019 February [Link] Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, Kubota K, Gemma A Abstract BACKGROUND/AIM: Malignant mesothelioma (MM) is an aggressive tumor with poor prognosis. The establishment of a new diagnostic and therapeutic approach for MM is expected. This study investigated the diagnostic significance of tenascin XB […]

Comments Off on Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.

Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Lung Cancer 2019 January [Link] Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, Borg E, Falzon M, Nankivell M, Nicholson AG, Janes SM Abstract Introduction BRCA1 associated protein-1 (BAP1) is a key tumor driver in mesothelioma and a potential biomarker predicting response to several targeted therapies in clinical testing. Whether it also modulates response to cytotoxic chemotherapy is undetermined. This study used […]

Comments Off on Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.